GlassScriptPhysician profile
Charles D Cook
NPI 1407288459
$5,967.91
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,725 · 2022: $2,835 · 2023: $232 · 2024: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,089.53 | 2021-2023 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $598.87 | 2021-2024 | Airsupra, Farxiga |
| Abbvie INC. | $536.59 | 2021-2022 | |
| Glaxosmithkline, LLC. | $454.94 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.08 | 2021-2023 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Amgen INC. | $309.34 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $267.56 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $264.21 | 2022 | |
| Astellas Pharma US INC | $240.24 | 2021-2022 | |
| Pfizer INC. | $235.63 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $234.28 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $173.60 | 2021-2022 | |
| Lilly USA, LLC | $150.56 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $124.35 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $122.18 | 2022-2024 | Rexulti |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $114.04 | 2022 | |
| Daiichi Sankyo INC. | $108.04 | 2021 | |
| Sunovion Pharmaceuticals INC. | $66.38 | 2022 | |
| Arbor Pharmaceuticals, INC. | $58.52 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.26 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $39.77 | 2022 | |
| Esperion Therapeutics, INC. | $39.38 | 2021 | |
| Abbott Laboratories | $38.75 | 2021-2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $34.04 | 2021 | |
| Biogen, INC. | $32.02 | 2021-2022 | |
| Almatica Pharma LLC | $31.39 | 2021-2022 | |
| Corium, LLC | $25.66 | 2022-2023 | Adlarity |
| Ironwood Pharmaceuticals, INC | $24.70 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.21 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.99 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.48 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $15.46 | 2023 | Nuzyra |
| Eisai INC. | $14.00 | 2021 | |
| Medicure Pharma INC. | $13.64 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.03 | 2021 | |
| Amarin Pharma, INC. | $11.50 | 2021 | |
| Genentech USA, INC. | $10.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.